ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Sets Initial R01 Payline At 18th Percentile Under CR.

November 24, 2000

NCI Plans $30 Million In Patient-Oriented Chemoprevention research In Next 5 Years

December 6, 1996

Contract For NCI CIS Service Center Awarded To Fred Hutchinson

December 11, 2009

Obituary: Gregory Foltz, Swedish Medical Center Neurosurgeon

July 12, 2013

ASCO, COA Present Plans For Cancer CareBeyond the Fee-For-Service Pay Structure

January 24, 2014

In Brief: Grants To Get Biggest Share Of NCI’s Extra $74 Million; A PR Failure In Pittsburgh

March 19, 1976